These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9457156)

  • 21. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.
    Schoonjans AS; Marchau F; Paelinck BP; Lagae L; Gammaitoni A; Pringsheim M; Keane MG; Ceulemans B
    Curr Med Res Opin; 2017 Oct; 33(10):1773-1781. PubMed ID: 28704161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
    Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB
    Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.
    Wadden TA; Berkowitz RI; Vogt RA; Steen SN; Stunkard AJ; Foster GD
    Obes Res; 1997 May; 5(3):218-26. PubMed ID: 9192396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring synergies in the treatment of obesity.
    Wadden TA
    Postgrad Med; 2001 Jun; 109(6 Suppl):29-33. PubMed ID: 19667565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anorectic medications in the treatment of obesity.
    Brune DB
    Arch Fam Med; 1994 Feb; 3(2):116. PubMed ID: 7994431
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effectiveness of serotonergic agonists in the treatment of obese patients].
    Mendoza Espejo R; Díaz Pérez de Madrid J; Buitrago F
    Aten Primaria; 1995 Oct; 16(6):364-6. PubMed ID: 7488690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of a weight-reduction program on total and regional body composition in obese postmenopausal women.
    Cordero-MacIntyre ZR; Peters W; Libanati CR; España RC; Howell WH; Lohman TG
    Ann N Y Acad Sci; 2000 May; 904():526-35. PubMed ID: 10865799
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical strategies for weight loss in the overweight and obese patient.
    Di Caro S; Hamad GG; Fernstrom MH; Schauer PR; Bonanomi G
    Minerva Gastroenterol Dietol; 2006 Dec; 52(4):415-30. PubMed ID: 17108871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [What effect does losing weight have on hypertension?].
    Engeli S
    MMW Fortschr Med; 2003 Jul; 145(27-28):44. PubMed ID: 14587188
    [No Abstract]   [Full Text] [Related]  

  • 31. Mitral valve disease associated with use of anorexigenic medications.
    Cheng TO
    Ann Thorac Surg; 1998 Jan; 65(1):298-9. PubMed ID: 9456151
    [No Abstract]   [Full Text] [Related]  

  • 32. Prospects for the treatment of obesity.
    Proietto J
    Med J Aust; 1992 Sep; 157(6):363-4. PubMed ID: 1307233
    [No Abstract]   [Full Text] [Related]  

  • 33. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'.
    Griffen L; Anchors M
    Arch Intern Med; 1998 Jan; 158(1):102. PubMed ID: 9437392
    [No Abstract]   [Full Text] [Related]  

  • 34. Do these doctors give medicine a black eye?
    Rice B
    Med Econ; 2003 Dec; 80(24):58-62, 65, 69. PubMed ID: 14733056
    [No Abstract]   [Full Text] [Related]  

  • 35. Addiction potential of phentermine prescribed during long-term treatment of obesity.
    Hendricks EJ; Srisurapanont M; Schmidt SL; Haggard M; Souter S; Mitchell CL; De Marco DG; Hendricks MJ; Istratiy Y; Greenway FL
    Int J Obes (Lond); 2014 Feb; 38(2):292-8. PubMed ID: 23736363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of weight management.
    Meisler JG
    J Womens Health Gend Based Med; 1999 Sep; 8(7):889-99. PubMed ID: 10534292
    [No Abstract]   [Full Text] [Related]  

  • 37. The Phen-Fen no-no with general anesthesia.
    Giese SY
    Plast Reconstr Surg; 1998 Feb; 101(2):552-3. PubMed ID: 9462811
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.
    Kim KK; Cho HJ; Kang HC; Youn BB; Lee KR
    Yonsei Med J; 2006 Oct; 47(5):614-25. PubMed ID: 17066505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study.
    Truant AP; Olon LP; Cobb S
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):726-38. PubMed ID: 4629111
    [No Abstract]   [Full Text] [Related]  

  • 40. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.